Screening
Your Organisational Guidance
ebpracticenet urges you to prioritise the following organisational guidance:
Évaluation du risque cardiovasculaire en première lignePublished by: Domus MedicaLast published: 2010Cardiovasculaire risicobepaling in de eerste lijnPublished by: Domus MedicaLast published: 2020There is a well-established link between hypercholesterolaemia and coronary heart disease, and a high incidence and prevalence of hypercholesterolaemia in high-income countries. Lowering of low-density lipoprotein cholesterol (LDL-C) leads to a reduction of cardiovascular events in moderate- to high-risk patients.
The American Association of Clinical Endocrinologists and American College of Endocrinology guidelines recommend that all adults 20 years of age or older should be evaluated for dyslipidaemia every 5 years, with more frequent testing recommended as patients become older.[50] In the UK and Europe, lipid screening usually starts at age 40.[41][51] Screening may begin earlier for those with diabetes in childhood or a family history of dyslipidaemia, and the 2018 American College of Cardiology/American Heart Association guidelines additionally recommend screening as early as age 2 years for those with a family history suggestive of early atherosclerotic cardiovascular disease (ASCVD).[44] The US Preventive Services Task Force found that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in asymptomatic children and adolescents aged 20 years or younger.[52]
Use of this content is subject to our disclaimer